Other terms
SK&F D 39162,SK&F-39162,SK&F 39162,SK&F39162,Ridauran,Robapharm Brand of Auranofin,Auranofin Robapharm Brand,Crisinor,Rubio Brand of Auranofin,Auranofin Rubio Brand,Ridaura,SmithKline Beecham Brand of Auranofin,Recordati Brand of Auranofin,Auranofin Recordati Brand,Yamanouchi Brand of Auranofin,Auranofin Yamanouchi Brand
Description
Auranofin: An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.
Pervious tree
Next tree
Other locations in tree
Legal notice
The U.S. National Library of Medicine is the creator, maintainer, and provider of the data above.
The version of the data is 2010 MeSH. Last reviewed April 26, 2010. No modification has been made in the content of the file.
Neither the United States Government, nor any of its agencies, contractors, subcontractors or employees makes any warranties, expressed or implied, with respect to data contained in the database, and, furthermore, assumes no legal liability for any party's use, or the results of such use, of any part of the database.
You will not assert any proprietary rights to any portion of the database, or represent the database or any part thereof to anyone as other than a United States Government database.
The MeSH data carry an international copyright outside the United States, its Territories or Possessions. These terms and conditions are in effect as long as the user retains any of the MeSH data obtained from this site.